CPMV Stock Chart & Stats
$0.69
-$0.33(-35.52%)
At close: 4:00 PM EST
$0.69
-$0.33(-35.52%)
Day’s Range― - ―
52-Week Range$0.31 - $1.05
Previous CloseN/A
Volume102.00
Average Volume (3M)1.50K
Market Cap
$4.88M
Enterprise Value$6.37M
Total Cash (Recent Filing)$72.00
Total Debt (Recent Filing)$1.48M
Price to Earnings (P/E)―
Beta-1.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding7,242,137
10 Day Avg. Volume12
30 Day Avg. Volume1,505
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-0.30
Price to Sales (P/S)0.00
P/FCF Ratio-20.20
Enterprise Value/Market Cap1.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mosaic ImmunoEngineering News
CPMV FAQ
What was Mosaic ImmunoEngineering’s price range in the past 12 months?
Mosaic ImmunoEngineering lowest stock price was $0.31 and its highest was $1.05 in the past 12 months.
What is Mosaic ImmunoEngineering’s market cap?
Mosaic ImmunoEngineering’s market cap is $4.88M.
When is Mosaic ImmunoEngineering’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Mosaic ImmunoEngineering’s earnings last quarter?
Currently, no data Available
Is Mosaic ImmunoEngineering overvalued?
According to Wall Street analysts Mosaic ImmunoEngineering’s price is currently Overvalued.
Does Mosaic ImmunoEngineering pay dividends?
Mosaic ImmunoEngineering does not currently pay dividends.
What is Mosaic ImmunoEngineering’s EPS estimate?
Mosaic ImmunoEngineering’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mosaic ImmunoEngineering have?
Mosaic ImmunoEngineering has 7,242,137 shares outstanding.
What happened to Mosaic ImmunoEngineering’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mosaic ImmunoEngineering?
Currently, no hedge funds are holding shares in CPMV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mosaic ImmunoEngineering
Mosaic ImmunoEngineering Inc. is an early-stage biotechnology firm dedicated to the advancement and commercialization of an immunomodulatory platform technology. This innovative platform aims to provide therapeutic solutions for cancer and infectious diseases in both human and animal health. The company's core product is MIE-101, a nanoparticle-based treatment sourced from the cowpea mosaic virus, which has demonstrated non-infectious characteristics in mice, dogs, and humans. Headquartered in Novato, California, the company commenced operations in 2020.
Technical Analysis
Theriva Biologics
―
―
Indaptus Therapeutics
―
Enveric Biosciences
―
Artelo Biosciences
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---